Scaled for Success
Pioneering a new field of medicine requires more than vision. It takes a long-term commitment, sufficient resources and a collaborative approach to seize on the emerging breakthroughs that will define the future.
Casebia Therapeutics, a 50-50 joint venture between CRISPR Therapeutics and Bayer, was created to accelerate the field of gene editing therapeutics today, and for the long haul. Drawing on CRISPR/Cas9 technology and expertise from CRISPR Therapeutics and the distinctive disease know-how and protein engineering capabilities of Bayer, we are working to redefine what’s possible for patients with a wide range of inherited diseases.
There are more than 6,000 human diseases known to be caused by specific genetic mutations. Our understanding of these diseases has improved dramatically in recent years, but the ability to treat patients remains inadequate—in many cases, because current treatment options fail to address the underlying genetic cause of the disease.
Casebia’s CRISPR/Cas9 gene editing technology—co-invented by Emmanuelle Charpentier, founder of CRISPR Therapeutics—has the potential to directly treat, and in some cases cure, genetic disease by precisely altering specific sequences of disease-causing DNA.
To discover, develop and deliver new gene-based medicines, we have gathered industry leaders in gene editing, drug discovery and development and empowered them with the latest technology and an organizational structure that simultaneously allows the agility of a start-up, and access to the resources and insight of established industry leaders.
In short, we have the team, the tools and the focus to turn aspiration into reality.
President and CEO,
Head of Bayer Life Science Center,
Chief Executive Officer,
Head of Research and Development, Pharmaceutical Division,
Chairman of the Board
Founder and President,